Pharmaceuticals

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years...

2021-03-26 21:31 4079

Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results

SUZHOU, China, March 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial result...

2021-03-26 20:54 6991

InnoCare Releases 2020 Annual Results and Business Highlights

BEIJING, March 26, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2020 annual results which ended onDec. 31, 2020. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "During 2020...

2021-03-26 19:39 6270

Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)

Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, March 26, 2021 /PRNewswire/ --...

2021-03-26 16:00 3606

Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed publicati...

2021-03-26 08:38 3245

Antengene Announces Financial Results for Full Year 2020

SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" or "the company", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in h...

2021-03-26 08:00 4452

Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion

WUHAN, China, March 26, 2021 /PRNewswire/ -- Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment ofUS$190 million investment from institutional investors, and over $100 million investment has already been closed today. This round of fin...

2021-03-26 08:00 5945

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

CINCINNATI, March 26, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...

2021-03-26 05:19 3676

Antengene Appoints Kevin Lynch as Chief Medical Officer

SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in ...

2021-03-25 23:26 4581

Antengene Appoints Bo Shan as Chief Scientific Officer

SHANGHAI, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announc...

2021-03-25 22:36 5991

CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020

SUZHOU, China, March 25, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today reported financial results and business highlights for the f...

2021-03-25 22:03 5124

China Eastern Flies Vaccines to Dominican Republic

SHANGHAI, March 25, 2021 /PRNewswire/ -- A new batch of vaccines developed by Chinese pharmaceutical companies Sinopharm and Sinovac was delivered onMarch 18 by China Eastern Airlines fromBeijing to the Dominican Republic, according to theShanghai-based airline.

2021-03-25 19:22 2154

BioNTech Chairman Helmut Jeggle joins the Board of IQM Quantum Computers

MUNICH, March 25, 2021 /PRNewswire/ -- IQM Quantum Computers  (IQM) announced today that Helmut Jeggle has joined IQM´s board of directors. He joins the company during a transformational phase. After successfully closing its Series A funding round and selling its first q...

2021-03-25 18:29 3555

111 Signs Strategic Cooperation Agreement with Jianming Pharmaceutical to Develop Chronic Disease Management Platform

SHANGHAI, March 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (Nasdaq: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, and Jianming Pharmaceutical Group ("Jianming Pharmaceutical"), a p...

2021-03-25 17:00 2787

AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine

AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou,...

2021-03-25 17:00 3563

Nippon Express Obtains IATA CEIV Pharma Certification for Temperature-controlled Facility near Narita Airport

TOKYO, March 25, 2021 /PRNewswire/ -- Nippon Express Co., Ltd. has obtained IATA CEIV Pharma (*) pharmaceutical transport quality certification for its Narita Temperature-Controlled Hub (NTCH) and for transport operations between NTCH and Narita Airport, effectiveMarch 15. This is the second pha...

2021-03-25 15:00 2980

Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar

TAIPEI, March 24, 2021 /PRNewswire/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. E...

2021-03-24 23:27 4925

Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation

SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Ev...

2021-03-24 19:07 2741

Forest Hills Lab is filing an IND to initiate a clinical phase 2 study on Parkinson's disease with the US FDA

HONG KONG, March 23, 2021 /PRNewswire/ -- Forest Hills Partners Hong Kong Limited (also known as Forest Hills Lab) is ready to file an Investigative New Drug (IND) application with the US FDA inApril 2021 to assess tolerability and efficacy with one of its drug candidates, namely FHL-301 in a pha...

2021-03-24 12:25 5856

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy * GAVRETO is the first approved selective RET inhibitor in China and first approved precision therapy for CStone SUZHOU,...

2021-03-24 10:46 5942